On the other hand, miR-4711-5p exhibited the strongest inhibitory effect on tumour growth when compared with other miRNAs that have been shown to suppress KLF5 in other cancers (i.e. miR-21, miR-152, miR-153 and miR-44826–29), as well as a putative anti-oncomiR, miR-34a, which was used in the first clinical trial against human solid tumours.48,49 Moreover, administration of miR-4711-5p displayed an outstanding tumour-suppressive effect even compared with miR-34a in five sets of CRC cell cultures that were prepared from CRC patients after surgical resection. The gene discussed is KLF5; the disease is cancer.